COMMUNIQUÉS West-GlobeNewswire

Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
19/05/2026
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Demonstrated >90% editing of SERPINA1 [...]
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
19/05/2026
Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. ( [...]
XORTX Announces Closing of US$5 Million Public Offering
19/05/2026
CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]
EyePoint Announces Participation at Upcoming Investor Conferences
19/05/2026
WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]
Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical Conferences
19/05/2026
CHICAGO, May 19, 2026 (GLOBE NEWSWIRE) -- Vanqua Bio , a clinical-stage biopharmaceutical company, announced that the company will present interim data from its Phase 1b study at World Parkinson’s Congress and the GBA1 [...]
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
19/05/2026
– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – MELBOURNE, [...]
Science 37 and Tufts CSDD Publish Landmark Study on Direct-to-Patient Clinical Trial Site Performance, Outperforming Industry Benchmarks
19/05/2026
MORRISVILLE, N.C., May 19, 2026 (GLOBE NEWSWIRE) -- Science 37 today announced the publication of a new analysis in Applied Clinical Trials in collaboration with the Tufts Center for the Study of Drug Development (Tufts [...]
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
19/05/2026
- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT - WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Zenas [...]
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
19/05/2026
Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide's favourable hepatic profile in patients with Metabolic Dysfunction-associated Steatohepatitis (MASH), addressing a critical concern for clinicians [...]
ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium
19/05/2026
Garching / Munich, May 19 , 2026 –– ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that dosimetry data from its Phase 3 COMPETE trial will be provided in a [...]
Leo International Precision Health AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
19/05/2026
Leo International Precision Health AG: Total Voting Rights Announcement Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 19. May 2026 / 14:00 [...]
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
19/05/2026
Milestone advances commercial and manufacturing readiness ahead of anticipated pivotal study scale-up BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") ( [...]
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
19/05/2026
Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus’ proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology [...]
Matisse Pharmaceuticals receives FDA IND clearance for isupartob sodium
19/05/2026
Geleen, May 19 th , 2026 Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, today announced that the U.S. Food and Drug Administration (FDA) has cleared [...]
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
19/05/2026
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
GenoSafe advances CLIA pathway for transatlantic ATMP development
19/05/2026
GenoSafe advances CLIA pathway for transatlantic ATMP development CLIA registration enables GenoSafe to support testing of samples from U.S.-based patients enrolled in clinical trials. This milestone strengthens [...]
HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy
19/05/2026
HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy Former ImCheck Therapeutics clinical leader joins HEPHAISTOS-Pharma as the company prepares to advance its lead [...]
FEATOL Introduces Ergonomic Wrist Support for Modern Repetitive Strain Challenges
19/05/2026
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- FEATOL has introduced the FEATOL 2 Pack Carpal Tunnel Wrist Brace, a wrist support solution for daily stabilization, pain relief, and recovery support. The brace is made for [...]
Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
19/05/2026
-- STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. -- Study to evaluate tertiary [...]

Pages